A broad discussion of the various forms of bacterial eye disease. The pathology and clinical management of each type will be covered in detail. The pharmocology of the various anti-infective medications will be discussed. Dosages, toxicity and adjunctive therapy will also be covered as well as appropriate laboratory testing procedures.

The use of topical and oral steroids represent a double-edged sword to the optometric physician. Their use can save or take away vision. Proper diagnosis, drug selection and patient monitoring are essential to appropriate use of these medications. This course highlights patient and drug selection to maximize therapeutic benefits and minimize risks.

This lecture will review the diagnostic pearls in evaluating a patient with chronic tearing and will discuss the candidacy, procedures and post-operative managements relevant to our patients.

This lecture will review some common and uncommon but serious lumps and bumps found on the lids and the expectations for management.

Therapeutic medications in eyecare changes frequently, requiring eyecare practitioners to stay up-to-date. This one-hour course highlights some of the "newer" medications used to treat ocular conditions.

This one-hour course emphasizes the judicious use of topical and systemic analgesic medications in the pharmaceutical management of ocular pain. Non-narcotic and narcotic medications, prescribing guidelines and clinical pearls will be covered.

This course will review the paradigm shift in medication usage and review the latest technologies in detecting and managing glaucoma.

Primary eye care practitioners commonly encounter allergic ocular diseases and now have numerous pharmaceutical treatment options. This course provides the practitioner with clinical management protocols for selecting the appropriate therapeutic agent and incorporates a clinical research update on ocular hypersensitivity mechanisms to assist the practitioner with proper diagnosis. The lecture emphasizes both differential diagnosis and clinical treatment pearls. Numerous case presentations illustrate the clinical treatment pearls.

This course discusses current and updated therapeutic protocols for the management of viral eye diseases. The lecture reviews the currently available ophthalmic drugs, future pharmaceutical agents and important clinical trial results. The lecture also highlights systemic disease correlations when appropriate. Numerous case studies illustrate the therapeutic principles and clinical treatment pearls for a variety of viral conditions.

This course presents a series of ocular disease cases in an interactive grand rounds format requiring therapeutic management skills by the primary eye care practitioner. The lecture includes a variety of cases including allergic, bacterial, viral, hypersensitivity, inflammatory, toxic, traumatic, Herpes simplex, Herpes-Zoster-varicella, etc. Each case presentation illustrates the chief complaint, history, clinical findings, differential diagnosis, management and treatment plan. Auxiliary tests, medical laboratory studies and surgical comanagement issues are reviewed as appropriate.

This lecture updates the primary eye care practitioner on the current treatment strategies for uveitis. The presentation covers current topical and systemic management options including current clinical protocols for appropriate medical laboratory testing. Numerous case studies illustrate the therapeutic management protocols and clinical treatment pearls.

A review and discussion of the various modalities available to change the refractive status of the human visual system and how to manage them in the optometric practice. This will include: corneal laser vision correction, phakic IOL's, clear lens exchange and presbyopic IOL's.

This course is an overview of modern cataract surgery and advancement of the intraocular lens technology and will provide clinicians with pre-operative selection and testing of patients as well as post-operative care of cataract patients and complications.

The development of agents to target pathologic processes in the retina while preserving retinal tissue and function has generated a true paradigm shift in our approach to the management of retinovascular disorders and in particular age related macular degeneration. The indications and uses for various agents including verteporfin, Pegaptanib, Bevacizumab (Avastin™), and Ranibizumab (Lucentis™) will be discussed.